https://www.arcutis.com/arcutis-zoryve-roflumilast-cream-receives-strong-recommendation-in-american-academy-of-dermatology-first-ever-pediatric-atopic-dermatitis-guidelines/
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of...
Apr 28, 2026 - Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical...
american academyroflumilastcreamreceivesstrong
https://www.everydayhealth.com/eczema/new-atopic-dermatitis-treatment-works-quickly-fewer-side-effects/
FDA Approves Zoryve (Roflumilast) Cream 0.15 Percent for Atopic Dermatitis
Jul 10, 2024 - The new topical treatment works quickly and has fewer side effects than other treatments for this common type of eczema, and it can be used for any length of...
atopic dermatitisfdaroflumilastcreampercent
https://www.zoryve.com/atopic-derm
ZORYVE® (roflumilast) Cream 0.15% (ages 6+) and 0.05% (ages 2-5) for Mild to Moderate Eczema...
Discover ZORYVE cream—a once-daily, nonsteroidal treatment for mild to moderate eczema (atopic dermatitis). See Safety and Product Info.
mild to moderateroflumilastcreamageseczema
https://www.academia.edu/143383907/Roflumilast_partially_reverses_smoke_induced_mucociliary_dysfunction
(PDF) Roflumilast partially reverses smoke-induced mucociliary dysfunction
Aug 11, 2025 - Background: Phosphodiesterases (PDEs) break down cAMP, thereby regulating intracellular cAMP concentrations and diffusion. Since PDE4 predominates in airway...
pdfroflumilastreversessmokeinduced
https://thedermdigest.com/arcutis-submits-snda-to-the-us-fda-for-roflumilast-cream-0-05-in-infants-with-ad/
Arcutis Submits sNDA to the US FDA for Roflumilast Cream 0.05% in Infants With AD - The Dermatology...
Apr 28, 2026 - Arcutis submitted a sNDA to the FDA seeking to expand the indication for roflumilast cream 0.05% to infants down to 3 months.
to the